A Study of GR1802 in Participants With Chronic Sinusitis With Nasal Polyps

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Clinical Trial Evaluating the Efficacy, Safety, and Immunogenicity of GR1802 in Participants With Chronic Rhinosinusitis With Nasal Polyps

The goal of this clinical trial is to learn if GR1802 works to treat severe chronic rhinosinusitis with nasal polyps (CRSwNP) in adults. It will also learn about the safety of GR1802. The main questions it aims to answer are:

1. Does GR1802 reduce the need for surgery and systemic corticosteroid use？
2. What medical problems do participants have when taking GR1802?

Researchers will compare GR1802 to a placebo (a look-alike substance that contains no drug) to see if GR1802 works to treat CRSwNP.

Participants will:

Take GR1802 or a placebo once every 2 weeks for 13months. Visit the clinic once every 2 weeks for checkups and tests. Keep a diary of their symptoms and the dosage and number of times they use mometasone furoate nasal spray.

Study Overview

• Status: Active, not recruiting
• Conditions: Chronic Rhinosinusitis With Nasal Polyps
• Intervention / Treatment: Drug: GR1802; Drug: Placebo

Detailed Description

A randomized, double-blind, placebo-controlled, multi-center clinical trial was designed. The clinical trial was divided into 4 stages: screening/introduction period, double-blind treatment period , maintenance treatment period and safety follow-up period.

The clinical trial aimed to evaluate the efficacy, safety and immunogenicity of GR1802 injection in CRSwNP participants.

• Study Type: Interventional
• Enrollment (Estimated): 228
• Phase: Phase 3

Contacts and Locations

Study Locations

• China
  • Beijing, China
    • Beijing Tongren Hospital, Capital Medical University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Diagnosed as CRSwNP and treated with systemic glucocorticoid within 2 years before screening; and/or those who had undergone surgery for nasal polyps before screening.
• An endoscopic bilateral NPS at screening/lead-in period and the baseline period of at least 5 out of a maximum score of 8 (with a minimum socre of 2 in each nasal cavity).
• Nasal congestion/blockade/obstruction with moderate or severe symptom severity at at screening period (score 2 or 3 ) .
• Willing to sign an informed consent, able to comply with clinic visits and study-related procedures as per protocol.

Exclusion Criteria:

• Biologic therapy within 5 half-lives or within 10 weeks before baseline.
• Anti-IL-4Rα antibody before screening.
• An experimental drug within 5 half-lives or 1 months before baseline.
• Systemic immunosuppressant to treat inflammatory disease or autoimmune disease within 2 months or 5 half-lives before baseline.
• Initiation of allergen immunotherapy within 3 months before screening.
• Participants receiving leukotriene antagonist/modifier before screening unless on continous treatment for at least 30 days.
• Participants with FEV1 50% or less of predicted normal were excluded.
• Participants who have undergone any intranasal and/or sinus surgery within 6 months before screening.
• Acute sinusitis or upper respiratory infection within a defined time period before screening.
• A nasal cavity tumor (malignant or benign).
• Evidence of fungal rhinosinusitis.
• Presence of another diagnosis associated with nasal polyps (i.e., eosinophilic granulomatosis with polyangiitis, granulomatosis with polyangiitis, Young's syndrome, cystic fibrosis).
• Rhinitis medicamentosa.
• Nasal septal deviation occluding at least one nostril.
• Antrochoanal polyps.
• Pregnant or lactating woman.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: GR1802 group; GR1802 300mg is administrated every 2 weeks (first dose doubled) for a total of 26 doses, of which an additional 2 ml of placebo is given at week 24.	Drug: GR1802; GR1802 will be administered SC.
Placebo Comparator: placebo group; Placebo is administered every 2 weeks for the first 16 weeks. GR1802 is given every 2 weeks from week 24 to W50.	Drug: Placebo; The placebo will be administered SC.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change from baseline in nasal polyps score at week 24.	Nasal polyps score score ranges from 0-8 (sum of 0-4 for each nasal passage scores), higher score means a worse outcome.	At week 24
Change from baseline in nasal congestion score at week 24.	Nasal congestion score (0-3), higher score means worse nasal symptom.	At week 24

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change from baseline in reduction/loss of smell at weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56 and 60.	The reduction/loss of smell severity was reported by the participant on a daily basis using a 0 to 3 categorical scale. Higher score means a worse sense of smell.	From baseline to week 60
Change from baseline in nasal discharge (anterior/posterior) at weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56 and 60.	The nasal discharge severity was reported by the participant on a daily basis using a 0 to 3 categorical scale. Higher score means a worse nasal symptom.	From baseline to week 60
Change from baseline in Total Nasal Symptom Score (TNSS) at weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56 and 60.	TNSS score (0-9). Higher score means worse nasal symptom.	From baseline to week 60
Change from baseline in nasal endoscopy nasal polyps score in participants with a high power field of vision < 55 eosinophil granulocytes in nasal polyp tissue at week 24.	Nasal polyps score score ranges from 0-8 (sum of 0-4 for each nasal passage scores), higher score means a worse outcome.	At week 24
Change from baseline in nasal congestion score in participants with a high power field of vision < 55 eosinophil granulocytes in nasal polyp tissue at week 24.	Nasal congestion score (0-3), higher score means worse nasal symptom.	At week 24
Change from baseline in nasal polyps score at weeks 2、4、8、16、32、40、52 and 60.	Nasal polyps score score ranges from 0-8 (sum of 0-4 for each nasal passage scores), higher score means a worse outcome.	From baseline to week 60
Proportion of participants with improvement by at least 1 point in nasal polyps score at weeks 2、4、8、16、24、32、40、52 and 60.	Nasal polyps score score ranges from 0-8 (sum of 0-4 for each nasal passage scores), higher score means a worse outcome.	From baseline to week 60
Proportion of participants with improvement by at least 2 point in nasal polyps score at weeks 2、4、8、16、24、32、40、52 and 60.	Nasal polyps score score ranges from 0-8 (sum of 0-4 for each nasal passage scores), higher score means a worse outcome.	From baseline to week 60
Time to first response (≥1 point improvement) in nasal polyps score.	Nasal polyps score score ranges from 0-8 (sum of 0-4 for each nasal passage scores), higher score means a worse outcome.	From baseline to week 60
Change from baseline in nasal congestion score at weeks 4、8、12、16、20、28、32、36、40、44、48、52、56 and 60.	Nasal congestion score (0-3), higher score means worse nasal symptom.	From baseline to week 60
Proportion of participants with improvement by at least 1 point in nasal congestion score at weeks 4、8、12、16、20、24、28、32、36、40、44、48、52、56 and 60.	Nasal congestion score (0-3), higher score means worse nasal symptom.	From baseline to week 60
Proportion of participants with improvement by at least 2 point in nasal congestion score at weeks 4、8、12、16、20、24、28、32、36、40、44、48、52、56 and 60.	Nasal congestion score (0-3), higher score means worse nasal symptom.	From baseline to week 60
Change from baseline in Lund-Mackay score at week 24 and 52.	The range of LM score is 0-24. Higher score means worse rhinosinusitis.	From baseline to week 60
Change from baseline in 22-item Sinonasal Outcome Test (SNOT-22) at weeks 2, 4, 8, 16, 24, 32, 40, 52 and 60.	The range of SNOT-22 score is 0 to 110. Higher scores indicating more severe disease.	From baseline to week 60
Change from baseline in University of Pennsylvania Smell Identification Test (UPSIT) at weeks 2, 4, 16, 24, 32, 40, 52 and 60.	UPSIT score (0-40). Higher score means better sense of smell.	From baseline to week 60
Change from baseline in five-level EuroQol five-dimensional questionnaire (EQ-5D-5L) at weeks 4、16、24、40、52 and 60.	The EQ-5D-5L descriptive system comprises five dimensions (MOBILITY, SELF-CARE, USUAL ACTIVITIES, PAIN / DISCOMFORT and ANXIETY / DEPRESSION), and each dimension has five response levels: no problems, slight problems, moderate problems, severe problems, unable to/extreme problems. The respondent is asked to indicate his/her health state by checking the box next to the most appropriate response level for each of the five dimensions.	From baseline to week 60
Safety parameters.	Incidence of treatment-emergent adverse events (TEAEs), incidence of treatment-emergent serious AEs (TESAEs), etc.	From baseline to week 60
Pharmacokinetics, include Ctrough, etc.	GR1802 concentrations were measured in CRSwNP population using sparse sampling (samples collected at predose, during treatment, and the follow up period).	From baseline to week 60
Pharmacodynamics.	Levels of the type 2 inflammation biomarkers were assessed as markers for disease activity/severity.	From baseline to week 60
Immunogenicity, include ADA and Nab.	Anti GR1802 antibody status was determined at baseline and at prespecified time points.	From baseline to week 60

Collaborators and Investigators

• Sponsor: Genrix (Shanghai) Biopharmaceutical Co., Ltd.
• Investigators: Principal Investigator: Luo Zhang, Doctor, Beijing Tongren Hospital

Study record dates

Study Major Dates

• Study Start (Actual): September 19, 2024
• Primary Completion (Estimated): March 1, 2026
• Study Completion (Estimated): October 1, 2026

Study Registration Dates

• First Submitted: July 8, 2024
• First Submitted That Met QC Criteria: July 18, 2024
• First Posted (Actual): July 23, 2024

Study Record Updates

• Last Update Posted (Actual): March 3, 2026
• Last Update Submitted That Met QC Criteria: February 28, 2026
• Last Verified: July 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathological Conditions, Anatomical; Respiratory Tract Infections; Infections; Respiratory Tract Diseases; Nose Diseases; Otorhinolaryngologic Diseases; Rhinitis; Sinusitis; Paranasal Sinus Diseases; Rhinosinusitis; Polyps; Nasal Polyps
• Other Study ID Numbers: GR1802-007

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No